NCT04756960View on ClinicalTrials.gov

Evaluation of the Absolute Bioavailability and Mass Balance of CHF6001 (Tanimilast) in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 10, 2021

Primary Completion Date

April 29, 2021

Study Completion Date

April 29, 2021

Conditions

Chronic Obstructive Pulmonary Disease (COPD)COPD

Interventions

DRUG

CHF6001

4 inhalations of CHF6001 800 µg/20 mg NEXThaler® dry-powder inhaler (DPI), (total dose of 3200µg) co-administered with an intravenous microdose (18.5µg (18.5 kBq)) of \[14\^C\]-labelled CHF6001

Trial Locations (1)

LS2 9LH

Covance - Clinical Research Unit, Leeds

All Listed Sponsors

lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT04756960 - Evaluation of the Absolute Bioavailability and Mass Balance of CHF6001 (Tanimilast) in Healthy Subjects | Biotech Hunter | Biotech Hunter